Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Harry H. Yoon
Research Funding - Lilly
Johanna C. Bendell
No relevant relationships to disclose
Fadi S. Braiteh
No relevant relationships to disclose
Irfan Firdaus
No relevant relationships to disclose
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Sanofi
Research Funding - Bayer; Bristol-Myers Squibb; Incyte; Lilly; Sanofi
Allen Lee Cohn
Consultant or Advisory Role - Lilly
Nancy Lewis
No relevant relationships to disclose
Daniel M. Anderson
No relevant relationships to disclose
Edward Arrowsmith
No relevant relationships to disclose
Jonathan D. Schwartz
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Yihuan Xu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Minori Koshiji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Steven R. Alberts
No relevant relationships to disclose
Zev A. Wainberg
Research Funding - Lilly